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ABSTRACT: The aryl hydrocarbon receptor in-
teracting protein (AIP) founder mutation R304∗
(or p.R304∗; NM_003977.3:c.910C>T, p.Arg304Ter)
identified in Northern Ireland (NI) predisposes to
acromegaly/gigantism; its population health impact re-
mains unexplored. We measured R304∗ carrier frequency
in 936 Mid Ulster, 1,000 Greater Belfast (both in NI)
and 2,094 Republic of Ireland (ROI) volunteers and
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in 116 NI or ROI acromegaly/gigantism patients. Car-
rier frequencies were 0.0064 in Mid Ulster (95%CI =
0.0027–0.013; P = 0.0005 vs. ROI), 0.001 in Greater
Belfast (0.00011–0.0047) and zero in ROI (0–0.0014).
R304∗ prevalence was elevated in acromegaly/gigantism
patients in NI (11/87, 12.6%, P < 0.05), but not in ROI
(2/29, 6.8%) versus non-Irish patients (0–2.41%). Hap-
loblock conservation supported a common ancestor for
all the 18 identified Irish pedigrees (81 carriers, 30 af-
fected). Time to most recent common ancestor (tMRCA)
was 2550 (1,275–5,000) years. tMRCA-based simu-
lations predicted 432 (90–5,175) current carriers, in-
cluding 86 affected (18–1,035) for 20% penetrance. In
conclusion, R304∗ is frequent in Mid Ulster, result-
ing in numerous acromegaly/gigantism cases. tMRCA is
consistent with historical/folklore accounts of Irish gi-
ants. Forward simulations predict many undetected carri-
ers; geographically targeted population screening improves
asymptomatic carrier identification, complementing clin-
ical testing of patients/relatives. We generated disease
C© 2016 The Authors. ∗∗Human Mutation published by Wiley Periodicals, Inc.
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awareness locally, necessary for early diagnosis and im-
proved outcomes of AIP-related disease.
Hum Mutat 00:1–8, 2016. Published 2016 Wiley Periodicals,
Inc.∗
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Introduction
Germline aryl hydrocarbon receptor interacting-protein (AIP;
MIM# 605555) mutations cause autosomal dominant familial iso-
lated pituitary adenomas (FIPA) most commonly manifesting as
acromegaly or gigantism. Due to incomplete penetrance, the dis-
ease can also manifest as apparently sporadic pituitary adenoma
(PA) [Vierimaa et al., 2006; Daly et al., 2007; Leontiou et al., 2008].
Thesemostly GH-(somatotrophinomas) and/or prolactin-secreting
tumors develop in 17%–20% of AIP mutation (AIPmut) carriers,
typically before 30 years of age [Beckers et al., 2013; Herna´ndez-
Ramı´rez et al., 2015]. A diagnostic delay of several years from on-
set of symptoms is typical in somatotrophinomas, allowing tumor
expansion and prolonged GH excess, leading to significant compli-
cations [Reddy et al., 2010]. Despite major therapeutical advances,
managementof somatotrophinomas remains challenging, especially
in young patients with large/invasive tumors, two frequent charac-
teristics of AIPmut-positive patients [Beckers et al., 2013]. Iden-
tification of AIPmut carriers enables earlier clinical diagnosis and
treatment, improving outcomes [Herna´ndez-Ramı´rez et al., 2015].
To this end, predictive genetic testing of relatives of carriers is rec-
ommended [Korbonits et al., 2012]. General population screening is
costly but targeted screening could be cost effective when a disease-
associated allele is geographically highly localized [Schiavi et al.,
2012], as might be expected for evolutionarily recent mutations. To
date, population screening for genetic pituitary disease has not been
performed.
We have previously inferred a recent origin for the
NM 003977.3:c.910C>T (p.Arg304Ter) allele (p.R304∗ or R304∗)
in six FIPA pedigrees of Irish ancestry, including individuals born
in the 18th and 20th centuries, in a small region within Mid Ul-
ster, Northern Ireland (NI) [Chahal et al., 2011; Stals et al., 2011].
Using the age estimate of R304∗, we predicted through forward sim-
ulations a large number of current carriers [Chahal et al., 2011].
Therefore, we hypothesized that R304∗ would be frequent in the
Irish general population, in particular in Mid Ulster, and should
lead to a high proportion of R304∗-positive patients with soma-
totrophinomas. In this study, we conducted a population screen-
ing in Mid Ulster, in comparison with two large population sam-
ples from Greater Belfast, NI, and from the Republic of Ireland
(ROI). In addition,we identifiedR304∗ carriers amongpatientswith
acromegaly/gigantism in two main Irish endocrine referral centers
(Belfast and Dublin) and studied R304∗-positive patients in our In-
ternational FIPA Consortium database [Herna´ndez-Ramı´rez et al.,
2015]. We developed a new coalescent-based simulation approach
tomore precisely estimate the time tomost recent common ancestor
(tMRCA) of the Irish R304∗ allele based on haplotype data, and ap-
plied forward simulation to predict the number of carriers currently
alive.
Materials and Methods
Subjects
We performed a cross-sectional genetic analysis study of general
population adult individuals from three regions in Ireland: screen-
ing of volunteers from Mid Ulster (Local Government Districts
of Magherafelt, Cookstown, and Dungannon of NI) and genotyp-
ing of two large control groups from the Greater Belfast region—
PRIMEstudyparticipants [Lindenet al., 2012]—and theROITrinity
Biobank (Table 1). Sample size calculations and screening proce-
dures are described in the Supp. Methods.
A prospective cohort of unselected patients with acromegaly or
gigantism were recruited at the University Hospital in Belfast, the
only tertiary pituitary referral center in NI (n = 87, representing
60% of the NI Acromegaly Registry patients), and at the Beau-
mont Hospital, Dublin, the largest pituitary referral center in ROI
and closest to Mid Ulster (n = 29). Additional R304∗-positive pedi-
grees (five Irish and five non-Irish) and 13 AIPmut-negative Irish
FIPApedigrees [Herna´ndez-Ramı´rez et al., 2015]were also included.
Ethnicity—as assessed through family history—was unambiguous
for all pedigrees. R304∗-positive patients were previously reported
[Leontiou et al., 2008; Igreja et al., 2010; Chahal et al., 2011; Stals
et al., 2011; Williams et al., 2014; Herna´ndez-Ramı´rez et al., 2015],
while the other patients and subjects have not been previously de-
scribed. Patients were tested for AIPmuts, as previously described
[Igreja et al., 2010]. The following pedigree codes were used: “Sp”
(sporadic), “FIPA” (familial) and “Screening” (screening detected).
Tooth-extracted DNA from a pituitary giant’s skeleton at Trinity
College Dublin [Cunningham, 1892] was sequenced for AIPmut, as
previously described [Chahal et al., 2011]. The study protocol was
approved by the local Ethics Committees; all study participants gave
written informed consent.
Evolutionary Genetics and Statistical Analysis
Fourteen microsatellites (STR) covering 8.3 Mbp around the AIP
gene were genotyped in a minimum of one R304∗ carrier per pedi-
gree, as previously described [Chahal et al., 2011]. Haplotypes were
computed using PHASE [Stephens et al., 2001], incorporating phas-
ing information deduced from genotypes of closely related carriers
(three pedigrees) (Supp.Table S1). To estimate the tMRCAofR304∗-
containing haplotypes, we developed a novel inference methodol-
ogy combining an analytical result from coalescence theory and
simulations in an Approximate Bayesian Computation framework
[Beaumont et al., 2002]. First, we computed the tMRCA based on a
smaller haplotype block around R304∗ that was fully conserved in
18 Irish pedigrees (Supp. Table S2, row E). The full conservation al-
lowed us to apply an analytical formula [Donnelly et al., 1996]. The
tMRCA distribution resulting from this first step became the prior
distribution for the second step that used a simulation-based ap-
proach to incorporate additional conservation data of haploblocks
shared only between subsets of pedigrees. We simulated genealogies
with recombination and mutation using the program ms [Hudson,
2002] (Supp. Fig. S1) and generated distributions of tMRCA from
those simulations that were closest to the recombination and mu-
tation pattern inferred from our haplotype data (Supp. Fig. S2).
Results were based on sex-averaged genetic distances for AIP and
microsatellite loci, from HapMap v2 [The International HapMap
Consortium, 2007] and Rutgers v3 [Matise et al., 2007] genetic
maps (Supp. Table S1). Next, starting with tMRCAs randomly cho-
sen from the simulated tMRCA distribution (Supp. Fig. S3A and B),
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Table 1. Demographic Parameters of Irish Population Samples
Mid Ulster (n = 936) Greater Belfast (n = 1,000) ROI (n = 2,094)
Sample type Saliva DNA Blood DNA Blood DNA (n = 1,095) Buccal swab DNA (n = 999)
Males, count (proportion) 435 (46.5%) 1,000 (100%) 486 (44.4%) 559 (55.9%)
Age, years, median (range) 46 (18–85) 64 (58–72) 37 (19–69) 53 (18–76)
R304∗/wt AIP genotype 6 1a 0 0
wt/wt AIP genotype 930 999 1,095 999
R304∗ carrier frequency 6/936 1/1,000 0 0
aSeventy one years old male, normal height, no clinical signs of pituitary disease, normal serum hormone levels (basal IGF–I, prolactin, and GH serum levels during the oral
glucose tolerance test (GH–OGTT)), normal pituitary MRI examination—subsequently died of a pulmonary mesothelioma linked to asbestos exposure, aged 72 years; cascade
testing of relatives (Screening 2 pedigree) identified two unaffected R304∗ carriers: one male, 77 years, clinically unaffected and one female, 42 years, clinically unaffected, normal
pituitary MRI, random GH = 4.7 ng/ml, minimal IGF–I increase (1·07 × ULN), normal PRL, GH–OGTT not yet performed. wt, wild–type
we took a forward simulation approach to generate possible trajec-
tories for the allele frequency in the population, through binomial
sampling. This resulted in distributions of the expected present-day
number of carriers, which we conditioned to have at least the mini-
mum number of R304∗ carriers/generation observed in our dataset
(n = 27) (Supp. Fig. S3C and D). Detailed procedures, including
statistical analysis are described as Supp. Methods.
Results
Population Screening Reveals a Significantly High Carrier
Frequency of the R304∗ Allele in NI
Several families of patients suffering from acromegaly or gigan-
tism and carrying the IrishR304∗ allele came froma small geograph-
ical area within Mid Ulster in NI [Chahal et al., 2011; Stals et al.,
2011]. In order to estimate the local carrier frequency of R304∗, we
screened a population sample of 936 adults (Table 1), 90% of which
lived in Mid Ulster.
We identified six R304∗ heterozygous individuals (Supp. Table
S3), corresponding to a carrier frequency estimate of 0.0064 (95%
probability interval [CI]: 0.0027–0.013). Two related carriers, nega-
tive for personal or family history of PA, represented a novel R304∗
pedigree (Screening 1) (Supp. Tables S3 and S4). The remaining
carriers detected through screening were two patients previously di-
agnosed with somatotrophinomas (pedigrees Sp 4 and FIPA 4) and
two unaffected carriers from previously identified R304∗-positive
pedigrees Sp 4 and FIPA 1 (Supp. Tables S3 and S4). The R304∗
carrier status was significantly associated with a personal diagnosis
of PA (P < 0.001, Fisher’s exact test) and with a family history of PA
(FIPA or sporadic, P < 0.001, Fisher’s exact test). Mid Ulster screen-
ing revealedmany other PA patients, either directly (R304∗-negative
PA patients participating to screening) or indirectly (nonpartici-
pating PA patients mentioned as family history of R304∗-negative
screening subjects) (Supp. Table S3).
The Greater Belfast control population sample (n = 1,000, Table
1) revealed one R304∗-positive individual; corresponding to a car-
rier frequency of 0.001 (95% CI: 0.00011–0.0047). The carrier was
unaffected (clinical examination, hormonal measurements, and pi-
tuitary imaging), did not have a family history of PA, and cascade
testing of relatives revealed two carriers, both unaffected (Supp.
Table S4, Screening 2 pedigree).
In the ROI control population sample (n = 2,094, Table 1), no
R304∗-positive individuals were identified, corresponding to zero
carrier frequency (95% CI estimate 0–0.0014). This is in accord
with the absence/extremely low R304∗ carrier frequency observed
in diverse population samples included in the Exome Aggregation
Consortium (http://exac.broadinstitute.org/): two heterozygotes in
34,856 Europeans (0.000057) and none in 23,450 non-Europeans.
The Mid Ulster carrier frequency was significantly higher than the
ROI one (P = 0.0005, Fisher’s exact test), while the Greater Belfast
one did not differ from either ROI or Mid Ulster.
Extrapolation of our NI R304∗ carrier frequency estimates
(1/1,000 and 6/936) and 95% confidence intervals (CIs) to the pop-
ulation of Greater Belfast (579,276) andMid Ulster (139,011), com-
prising 40% of NI according to the 2011 census (http://www.ninis2.
nisra.gov.uk), yielded an estimatednumber of carriers of 1,470 (95%
CI: 439–4,530).
R304∗ is Common in Irish Patients with
Acromegaly/Gigantism
In order to characterize the extent of R304∗-related pituitary
disease in Ireland, we tested for AIP alleles in 116 patients with
acromegaly/gigantism from the two tertiary endocrine centers close
toMidUlster.We identified 11 (12.6%)R304∗-positive patientswith
somatotrophinomas in theNIAcromegaly Registry, Belfast, and two
(6.8%) in the Dublin center patients, while five NI (5.7%) and two
Dublin patients (6.8%) presented other AIP variants (Supp. Table
S5).
The R304∗-positive patients belonged to pedigrees FIPA 1–5 and
Sp 1–6 (Supp. Table S4). The R304∗ prevalence among NI patients
with somatotrophinomas was higher than that of large non-Irish
somatotrophinoma series [Tichomirowa et al., 2011; Cazabat et al.,
2012; Preda et al., 2014; Scho¨fl et al., 2014] (0–2.41%; P < 0.05,
Fisher’s exact test). Geographically, R304∗-positive patients with
somatotrophinomas predominated in Mid Ulster, where they, re-
markably, outnumbered AIPmut-negative patients (Fig. 1).
Irish R304∗-positive patients with somatotrophinomas (exclud-
ing those diagnosed prospectively, following predictive genetic test-
ing) displayed the known features of AIPmut-positive PAs: younger
age at disease onset/diagnosis, larger pituitary tumors, increased
frequency of gigantism and familial disease, compared to AIPmut-
negative patients (Table 2).
Our investigations revealed, however, a wider range of pheno-
types. While two patients, diagnosed as part of cascade testing in
families, harbored macroadenomas and underwent surgery, two
prospectively diagnosed R304∗-positive patients had pituitary mi-
croadenomas and four patients had disease onset after the age of 30
years [Herna´ndez-Ramı´rez et al., 2015]. Interestingly, none of the
patients carrying other AIP variants presented a PA family history.
All Irish R304∗ Pedigrees Share a Common Ancestor That
Lived Approximately 2,500 Years Ago
Having identified 13 R304∗-positive pedigrees through popula-
tion screening and testing of somatotrophinoma patients in Ireland,
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Figure 1. Geographical distribution of R304∗ allele carriers in Ireland, compared to AIPmut–negative patients with somatotrophinomas. R304∗
carriers, unaffected (R304∗ unaffected, green columns) and patients with somatotrophinomas (R304∗ GH, red columns) were compared to AIPmut–
negative patients with somatotrophinomas (AIP–neg GH, blue columns). Only subjects currently residing in Ireland were included; R304∗–positive
patients with other PA types (n = 5) are not shown. The map was arbitrarily divided into regions separated by dotted borders, red for Mid Ulster.
Ninety percent of the Mid Ulster screening subjects resided here, including all six R304∗ carriers. Each small graph summarizes data from the
region indicated by the corresponding arrow; the y–axis scale is identical for all graphs.
Table 2. Clinical Characteristics of Irish R304∗–Positive Somatotrophinoma Patients (NI Acromegaly Registry, Dublin patients and FIPA
Consortium database) Compared to AIPmut–Negative Irish Patients with Somatotrophinomas (NI and Dublin Patients)
AIP genotype
Heterozygous NM_003977.3:c.910C>T
n = 31
Homozygous wild-type
n = 96 P value
Median age (range) at onset (years) 17 (6–68) (n = 29) 38.5 (14–85) (n = 64) <0.0001
Median age (range) at diagnosis (years) 19.5 (7–68) (n = 30) 46 (19–85) (n = 95) <0.0001
Age <30 years at disease onset 27/31 (87.1%) 21/96 (21.9 %) <0.0001
Mean tumor size (mm) 23.8 ± 10.6 (n = 11) 17.2 ± 8.4 (n = 43) <0.05
Pituitary macroadenoma 22/24 (91.7%) 58/70 (82.9%) ns
Gigantism 18/31 (58.1%) 7/96 (7.3%) <0.0001
Family history of PA 24/31 (77.4%) 3/94 (3.2%) <0.0001
ns = not significant
we searched the International FIPA Consortium database for addi-
tional R304∗-positive pedigrees and identified 10 more, resulting in
a total of 23 R304∗-positive pedigrees (Fig. 2). These 10 additional
pedigrees were of diverse ethnic backgrounds: six from the UK: one
of English and five of Irish ancestry (FIPA 6–8, Sp 7 and 18th century
patient pedigrees) and four from other countries (Fig. 2 and Supp.
Table S4). In this database, we also identified 13 AIPmut-negative
Irish FIPA pedigrees (Supp. Table S6).
By reconstructing AIP gene region STR haplotypes in these 23
pedigrees, we determined that 18 of them shared a 0.2–1.95 Mbp
fully conserved haploblock around R304∗, as well as extended hap-
loblocks covering up to the entire 8.3 Mbp genotyped region (Fig.
2 and Supp. Table S1). These data support the existence of a re-
cent common ancestral carrier haplotype, the Irish R304∗ founder.
Fourteen of these 18 pedigrees were living in Ireland and the other
four had known Irish ancestry. The five non-Irish pedigrees did not
share significant haploblocks with the Irish ones or among each
other (Fig. 2), supporting the existence of recurrent independent
R304∗ mutation events at this mutation-prone CpG dinucleotide
[Vierimaa et al., 2006; Daly et al., 2007; Leontiou et al., 2008; Occhi
et al., 2010; Chahal et al., 2011; Tichomirowa et al., 2011; Cazabat
et al., 2012; de Lima et al., 2012; Cuny et al., 2013; Niyazoglu et al.,
2014].
The total number of Irish allele carrierswas 90 (37 affected, 53 un-
affected), 81 of which are currently alive (30 affected, 51 unaffected).
Seven of the 51 unaffected living carriers (13.7%) were detected
exclusively by population screening. The highest geographical con-
centration of R304∗ carriers in Ireland was observed in Mid Ulster,
both for affected (somatotrophinoma) and unaffected individuals
(Fig. 1), corresponding to eight different pedigrees. A third of the
Irish allele carriers (32%, 26/81) lived outside of Ireland: in England
(21), Scotland (2), Australia (2), and Canada (1).
To estimate the time to the most recent common ancestor (tM-
RCA) of the R304∗ carrier haplotypes among the Irish pedigrees, we
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Figure 2. Microsatellite haplotypes of chromosome 11q12.2–13.3 of R304∗–positive pedigrees. Irish (first two rows) and non–Irish pedigrees
(third row) are shown. Marker alleles are displayed as amplicon sizes. Dark shading: haploblock shared between all Irish pedigrees (0.2–1.95
Mbp long); light shading: additional shared haploblocks. Thick horizontal lines represent AIP alleles (black = wild–type, yellow = R304∗); intervals
between markers are not drawn to scale. Sp, sporadic PA. Haplotypes of 18th century patient, FIPA 1, 2, 3, 6, 7, FIPA UK, Romania, US (Italian), Sp
India and Sp Mexico pedigrees have been previously published (Chahal et al., 2011; Stals et al., 2011; Ramirez-Renteria et al., 2016).
developed a novel coalescent-based approach, combining analytical
calculations with haplotype simulation in an approximate Bayesian
computation [Beaumont et al., 2002] framework (Supp. Methods).
The tMRCA estimates of the Irish R304∗ haplotypes were 102 (51–
200) generations—median (95% CI)—based on HapMap and 101
(50–179) generations basedonRutgersmapgenetic distances (Supp.
Fig. S3A and B). These tMRCA distributions, for example, 51–200
generations (HapMap-based)overlap substantiallywith thoseprevi-
ously estimated: 17–150 generations [Chahal et al., 2011] (Pr(X>Y)
= 0.79). Assuming a generation time of 25 years [Chahal et al., 2011],
current estimates translate to 2,550 (1,275-5,000) years (HapMap)
and 2,525 (1,250-4,475) years (Rutgers). To estimate the number
of living subjects carrying the Irish R304∗ allele, forward simula-
tions conditioned on the number of observed carriers predicted 144
(30–1,725) and 141 (30–1,430) carriers per generation—median
(95% CI)—based on HapMap and Rutgers distances, respectively
(Supp. Fig. S3C and D). For three overlapping generations alive at
present, we estimate the current number of carriers as 3 × 144 =
432 (90-5,175; HapMap-based), corresponding to 86 (18–1,035) PA
patients, assuming 20% penetrance [Beckers et al., 2013].
Historical Irish Giants
The medical literature, as well as Irish folklore, holds numerous
descriptions of Irish giants. For some of these presumed pituitary
gigantism individuals there is historical and medical evidence for
the diagnosis (Supp. Table S7). We have tested DNA samples from
two historical giants for AIP-derived alleles: Charles Byrne (1,761–
1,783), born in Mid Ulster, who carried the Irish R304∗ allele [Cha-
hal et al., 2011] and Cornelius Magrath (1,736–1,760), born in
the Southern coast of Ireland and whose skeleton is conserved at
Trinity College, Dublin [Cunningham, 1892], who was R304∗-
negative. Five additional giants related to known R304∗ carriers
were presumed R304∗-positive: Subjects 6, 7, 11, 13, and 19 (Supp.
Table S7). Two unrelated Mid Ulster screening participants, R304∗-
negative themselves, provided photographic evidence of their ex-
tremely tall relatives, whom we included as historical Irish giants
(Fig. 3 and Supp. Table S7).
Discussion
In this study we demonstrated that the R304∗ AIP allele is present
in the general population of Ireland and its frequency varies ge-
ographically, from a high of 6/936 in Mid Ulster to 1/1,000 in the
Greater Belfast region (both inNI),while absent in aROIpopulation
sample. These differences were paralleled by the geographical dis-
tribution of R304∗-positive somatotrophinoma cases, representing
a significantly higher proportion of the somatotrophinoma patient
population in NI (12.6%), than in large published somatotrophi-
noma cohorts (maximum 2.41%) [Tichomirowa et al., 2011; Caz-
abat et al., 2012; Preda et al., 2014; Scho¨fl et al., 2014], while in the
ROI (Dublin center) this proportion was intermediate (6.8%). Fur-
thermore, the number of R304∗ carriers, both patients with soma-
totrophinomas and unaffected carriers, was highest in Mid Ulster.
These data strongly support our hypothesis that Mid Ulster has an
elevated R304∗ carrier frequency. However, 32% of the Irish R304∗
allele carriers were identified outside of Ireland, an observation
attributable to emigration. Another consequence of the increased
R304∗ carrier frequency in Ireland is that a large proportion (8 of
21, 38%) of Irish FIPA families are due to R304∗—the only AIPmut
identified in Irish FIPA so far.
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Figure 3. New evidence of historical Irish giants. (A) Subject 15 (Supp. Table S7), 211cm tall, from Maghera, Mid Ulster, uncle of a screening
participant, died of a hypertensive crisis one month after photograph was taken – 13th May 1918, Daily Sketch (Canadian newspaper). (B) Group of
Irish immigrants from Garvagh (a town close to Mid Ulster) after arrival in Western Australia, 1910. At center with the pole, Subject 16 (Supp. Table
S7), 213 cm tall; standing far left—unrelated subject with pronounced acromegalic features and tall stature (photograph from Garvagh Museum,
NI).
We demonstrate that all 18 R304∗-positive pedigrees of Irish
origin identified in the study inherited this allele from a com-
mon ancestor, the R304∗founder. In addition, we have shown that
R304∗ in pedigrees of English, Indian, Romanian, US Italian, Irish,
and Mexican origin derives from independent recurrent muta-
tional events [Chahal et al., 2011; Ramirez-Renteria et al., 2016].
Founder AIPmut alleles have also been identified through hap-
lotype analysis in Finnish [Vierimaa et al., 2006], Italian [Oc-
chi et al., 2010], Comoros [Cuny et al., 2013], and English [Sal-
vatori et al., 2014] populations, involving the p.Q14∗, p.R304∗,
p.G117Afs∗39, and p.F269 H275dup alleles, respectively, but the
present population frequency of all these founder alleles remains
unknown.
The refined coalescent simulation-based approximate Bayesian
computation approach we describe in this article provides a practi-
cal framework applicable to the estimation of tMRCA of identity-
by-descent alleles. Previous estimates using five pedigrees and a
simpler approach indicated a more recent common ancestor (66
generations, 95% CI = 17–150) [Chahal et al., 2011], although the
difference between new and previous estimates was not statistically
significant (Pr(X>Y) = 0.79). Although the founder probably lived
around 2,500 years ago, many of today’s carriers are concentrated in
a small region, suggesting a limited local migratory activity, despite
significant emigration in recent centuries. A population bottleneck
followed by reexpansion may explain the Mid Ulster R304∗ cluster,
although genetic drift in a constant sized or growing population is
consistent with observed frequencies and estimated age of this allele.
Persistence of the R304∗ allele in this population may suggest the
absence of, or only weak, purifying selection acting on this locus.
While R304∗-associated disease manifestations include hypopitu-
itarism, infertility, and shortened life span, low disease penetrance
will lead to a reduced selective disadvantage. Additionally, it is pos-
sible that there were inclusive fitness effects in the unaffected carrier
relatives of giants in thepast—perhaps as a result of elevated status—
that may have counterbalanced selective disadvantages in affected
carriers.
Identification of asymptomatic AIPmut carriers enables prospec-
tive early diagnosis of PAs, followed by prompt and effective treat-
ment, with improved chances of curing the disease and preventing
complications [Williams et al., 2014; Herna´ndez-Ramı´rez et al.,
2015]. To this end, cascade testing of AIPmut-positive patient
relatives is recommended; however, limited knowledge of family re-
lations, nondisclosure of information between relatives and nonac-
ceptance of testing may hinder these efforts. While carrier identifi-
cation in affected individuals is now becoming standard, detection
of unaffected carriers and their endocrine screening is a challenge
for the future. Supported by substantial patient and community
involvement, and by local media coverage, our study has created
awareness about AIP-related disease in Ireland, a necessary pre-
cursor for improved disease recognition and acceptance of genetic
testing. Although population screening is an unbiased approach to
carrier identification and could detect unaffected carriers without
family history of pituitary disease, further studies are needed to
justify this approach. Our study provides a proof-of-principle that
asymptomatic R304∗ carriers in Ireland can be identified through
population screening, by identifying two novel R304∗-positive pedi-
grees comprising a relatively large proportion (7/51, 13.7%) of the
known number of living unaffected carriers.
Given the tMRCA-predicted number of Irish R304∗ carriers (432,
95%CI: 90–5,175, 86 affected expected at 20%penetrance) and that
of known living carriers (81, of which 30 affected), we estimate the
number of undetected carriers as the difference between predicted
and known carriers, resulting in around 351 undetected carriers, in-
cluding 56 affected patients. Many of these undetected carriers may
actually live outside of Ireland, in countries with significant Irish
immigration, such as Great Britain, Canada, and Australia, where
32% of the known living Irish allele carriers reside, and the USA,
where AIP mutation testing has been limited to date. For NI, al-
ternative calculations by extrapolating population carrier frequency
estimates (Mid Ulster and Greater Belfast) to regional population
size (approximately 40% of NI), estimated 340 to 5,138 undetected
carriers, a range comparable to the tMRCA-predicted estimate.
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Several key features contribute to our study’s results and impact:
(1) patient and general public involvement in its design and con-
duct, (2) analysis of multiple Irish general population samples and
of a large unbiased patient cohort—the NI Acromegaly Registry, (3)
analysis of the largest R304∗ pedigree collection to date, thanks to
international collaboration, and (4) the incorporation of historical
and ancient DNA data into our analyses. In comparison, studies de-
scribing other AIPmut founder alleles, as well as our own previous
study of the Irish R304∗ allele, examined limited number of AIPmut
pedigrees and relatively small number of patients and population
controls, without providing estimates of population carrier frequen-
cies of these alleles and their geographical distribution [Vierimaa
et al., 2006; Occhi et al., 2010; Chahal et al., 2011; Cuny et al., 2013;
Salvatori et al., 2014].
Our study also has limitations. For practical reasons, only three
large Irish general population samples were screened for R304∗. Re-
garding PA types included in the study, we chose to include only
patients with somatotrophinomas, as this is the commonest PA type
inAIPmut carriers and the only one for which population-level data
were available. Patients with prolactinomas can also harborAIPmu-
tations, although significantly less frequently than somatotrophino-
mas [Tichomirowa et al., 2011;Cazabat et al., 2012;Cuny et al., 2013;
Preda et al., 2014]; the frequency of R304∗ in Irish patients with
prolactinomas remains to be determined. Sampling of patients with
somatotrophinomas from ROI was limited to the Dublin center,
based on its proximity to Mid Ulster, and fewer patients were ana-
lyzed, compared toNI. Future studies will help to better characterize
the R304∗ carrier frequency in the ROI general and PA patient pop-
ulations. Not all living members of R304∗-positive pedigrees were
available for genetic and clinical testing; this is a common difficulty
in genetic studies and clinical practice. Our evolutionary genetics
approach compensated for this, by estimating the number of unde-
tected allele carriers. Overall, we believe that these limitations have
relatively little effect on our conclusions.
Our work suggested several measures to address the challeng-
ing task of identifying the large number of undetected Irish R304∗
allele carriers, in order to improve the outcomes of PA patients.
(1) We propose R304∗ testing of patients of Irish descent with so-
matotrophinomas, especially ones with younger (<30 years of age)
onset, in Ireland and abroad, particularly in Great Britain, USA,
Canada, and Australia, where large Irish immigrant populations
exist. (2) Working closely together with patients and their commu-
nities has improved knowledge about AIP-related disease, which
may lead to earlier recognition of disease, and hopefully increased
acceptance of genetic testing. (3) Population screening in Ireland,
especially inMidUlster,might be effective, butmore study is needed
regarding the psychological and economic implications, as well as
further data on the clinical benefits of R304∗ screening [Herna´ndez-
Ramı´rez et al., 2015].
Our results open the way for future studies of several key aspects
of AIP-related disease. The Irish R304∗ cohort is unique in having
a large number of carriers sharing the same pathogenic gene al-
teration and promoter area within the fully conserved haploblock,
yet pedigrees display differences in penetrance and patient pheno-
types differ significantly. Currently, it is not known what influences
disease penetrance in AIPmut-positive individuals. Different indi-
vidual AIPmut alleles [Igreja et al., 2010] or classes (e.g., truncating
vs. nontruncating) [Herna´ndez-Ramı´rez et al., 2015], changes in
gene expression regulation [Cooper et al., 2013], and other epistatic
interactions may each play a role, as will other genetic and environ-
mental factors. Further genetic studies of this cohort could help the
identification of pituitary disease-modifying genes. Follow-up of
clinically-identified and screening-detected pedigrees will provide
new data about the natural history of disease in carriers, optimal
follow-up schedules, efficiency and outcome of population screen-
ing.
Irish folklore has numerous stories regarding Irish giants and
the remains of some of these giants have been studied in the past
[Cunningham, 1892; Frankcom and Musgrave, 1976; Chahal et al.,
2011].Ourdataprovides anexplanation for theobservationmadeby
the pioneering anthropologist James C. Prichard in 1826: In Ireland
men of uncommon stature are often seen, and even a gigantic form
and stature occur there much more frequently than in this island
[Britain] . . . We can hardly avoid the conclusion that there must
be some peculiarity in Ireland which gives rise to these phenomena
[Prichard, 1826].
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